Zhang Jiankang, Vice President of Walvax and President of its subsidiary Zerun Biotech: Eliminate Cervical Cancer Vaccine First Early Vaccination, Early Protection, Early Relief

Kunming High-tech Zone Delegation Visit Shanghai Zerun Biotech

Zerun Biotech Successfully Held a Celebration for the Marketing of Bivalent Cervical Cancer Vaccine

Shanghai Zerun Biotechnology Co., Ltd. Started Phase III Clinical Trial of Nonavalent HPV Vaccine

Yunnan Walvax, Shanghai Zerun and Beijing Walvax Received IND Approval for Recombinant SARS-CoV-2 Variant Vaccine

Shanghai Zerun Biotech awarded Municipal-acknowledged Enterprise Technology Center